Pfizer (PFE) Other Operating Expenses (2010 - 2017)

Pfizer has disclosed Other Operating Expenses across 8 years of filings, most recently posting -$6.7 billion for Q4 2017.

• In Q4 2017, Other Operating Expenses rose 12.65% year-over-year to -$6.7 billion; the TTM figure through Sep 2018 stood at -$6.7 billion (up 71.67% YoY), while the FY2017 annual figure was -$22.7 billion, up 6.78% from the prior year.
• Other Operating Expenses fell to -$6.7 billion in Q4 2017, from -$5.4 billion in the prior quarter.
• Over the last five years, Other Operating Expenses for PFE reached as high as $1.1 billion in Q2 2013 and fell as low as -$7.9 billion in Q4 2015.
• The 5-year median for Other Operating Expenses is -$5.3 billion (2017), against an average of -$3.9 billion.
• Annual changes were most pronounced in 2013 — Other Operating Expenses soared 255.52% — and 2015, when it tumbled 9796.23%.
• A 5-year view of Other Operating Expenses shows it stood at $18.0 million in 2013, then jumped by 194.44% to $53.0 million in 2014, then sank by 14983.02% to -$7.9 billion in 2015, then increased by 2.69% to -$7.7 billion in 2016, then increased by 12.65% to -$6.7 billion in 2017.
• According to Business Quant data, Other Operating Expenses over the past three periods registered -$6.7 billion, -$5.4 billion, and -$5.3 billion for Q4 2017, Q4 2017, and Q3 2017 respectively.